Novartis' TGFβ Targeted Antibody Secures FDA Orphan Drug Tag For Pancreatic Cancer
- The FDA has granted Orphan Drug Designation to Novartis AG's (NYSE: NVS) NIS793 in combination with standard of care chemotherapy to treat pancreatic cancer.
- NIS793 is a fully human anti-TGF-β IgG2 monoclonal antibody designed to inhibit the TGF-β pathway in tumor cells and modulate the tumor microenvironment.
- A Phase 2 study is ongoing, and a Phase 3 trial in the first-line metastatic pancreatic ductal carcinoma is planned to start enrolling patients later in 2021.
- Price Action: NVS shares are up 0.27% at $91.21 during the market session on the last check Tuesday.
- Related content: Benzinga's Full FDA Calendar.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs Orphan Drug Designation Pancreatic CancerBiotech News Health Care FDA General
